Goff Brian — SEC Form 4 filings
SEC reporting owner CIK 1546216. 15 Form 4 filings on record with FilingPulse; latest filed 2026-06-23.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2024-01-09 to 2026-06-23. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 17 legs across 11 filings — 145,621 shares, $4,829,025 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 48.
- Largest priced transaction: sale of 12,115 shares @ $48.84 ($591,697) in AGIOS PHARMACEUTICALS, INC., filed 2024-06-07.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | Chief Executive Officer, Director | 12 | — | 17 legs · 145,621 sh · $4,829,025 | 42 |
| Intellia Therapeutics, Inc. (NTLA) | Director | 3 | — | — | 6 |
Form 4 filings — Goff Brian
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-23 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 39,000 (derivative) @ $0 · Grant/award (A): 39,000 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Intellia Therapeutics, Inc. (NTLA) | Grant/award (A): 9,200 @ $0 · Grant/award (A): 13,300 (derivative) @ $0 | EDGAR |
| 2026-04-06 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 25,528 @ $0 · Sale (S): 12,472 @ $34.71 · Option exercise (M): 13,500 @ $0 · Sale (S): 6,596 @ $34.71 · Option exercise (M): 25,528 (derivative) @ $0 · Option exercise (M): 13,500 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 8,500 @ $0 · Sale (S): 3,870 @ $28.96 · Option exercise (M): 18,000 @ $0 · Sale (S): 8,267 @ $28.96 · Option exercise (M): 13,000 @ $0 · Sale (S): 5,918 @ $28.96 · +5 more | EDGAR |
| 2026-01-02 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 25,528 @ $0 · Sale (S): 12,473 @ $27.09 · Option exercise (M): 12,750 @ $0 · Sale (S): 6,230 @ $27.09 · Option exercise (M): 25,528 (derivative) @ $0 · Option exercise (M): 12,750 (derivative) @ $0 | EDGAR |
| 2025-08-12 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 22,691 @ $0 · Sale (S): 11,085 @ $36.67 · Option exercise (M): 22,691 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 25,527 @ $0 · Sale (S): 12,471 @ $33.54 · Option exercise (M): 12,750 @ $0 · Sale (S): 6,229 @ $33.54 · Option exercise (M): 25,527 (derivative) @ $0 · Option exercise (M): 12,750 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Intellia Therapeutics, Inc. (NTLA) | Grant/award (A): 8,000 @ $0 · Grant/award (A): 11,450 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 8,500 @ $0 · Sale (S): 4,153 @ $35.54 · Option exercise (M): 18,000 @ $0 · Sale (S): 8,794 @ $35.54 · Grant/award (A): 39,000 (derivative) @ $0 · Grant/award (A): 142,500 (derivative) @ $0 · +2 more | EDGAR |
| 2024-08-12 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 22,691 @ $0 · Sale (S): 11,091 @ $42.75 · Option exercise (M): 22,691 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Intellia Therapeutics, Inc. (NTLA) | Grant/award (A): 15,409 @ $0 · Grant/award (A): 22,297 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 25,527 @ $0 · Sale (S): 12,115 @ $48.84 · Option exercise (M): 25,527 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 8,500 @ $0 · Sale (S): 4,156 @ $32.57 · Grant/award (A): 54,000 (derivative) @ $0 · Grant/award (A): 195,500 (derivative) @ $0 · Option exercise (M): 8,500 (derivative) @ $0 | EDGAR |
| 2024-01-24 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 17,018 @ $0 · Sale (S): 7,635 @ $21.64 · Option exercise (M): 17,018 (derivative) @ $0 | EDGAR |
| 2024-01-09 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 25,527 @ $0 · Sale (S): 12,066 @ $22.99 · Option exercise (M): 25,527 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-09 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1546216 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →